CME for Physicians
CNE for Nurses
CPE for Pharmacists
CANCER EDUCATION FOR PHYSICIANS, NURSES, AND PHARMACISTS - Taught by the Experts

Co-Chairs

Edward B. Garon MD
Edward B. Garon , MD
Associate Clinical Professor
Department of Medicine
Director, Thoracic Oncology Program
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, CA
Disclosures
Contracted Research: AstraZeneca, BMS, Genentech, Eli Lilly, Merck, Novartis, Iovance, Mirati, Dynavax

I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
 
Paul A. Bunn MD
Paul A. Bunn , Jr. , MD
Distinguished Professor
James Dudley Chair in Lung Cancer Research
Professor, Medical Oncology
University of Colorado Denver
Denver, CO
Disclosures
Consulting Fees (e.g., advisory boards): AstraZeneca, BMS, Genentech, Lilly, Merck, Merck Serono, Takeda

I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
 
H Jack West MD
H Jack West , MD
Medical Director
Thoracic Oncology Program
Swedish Cancer Institute
President and CEO
Global Resource for Advancing Cancer Education (GRACE)
Seattle, WA
Disclosures
Consulting Fees (e.g., advisory boards): AstraZeneca, BMS, Boehringer Ingelheim, Genentech/Roche, Merck, Pfizer, Spectrum, Takeda
Fees for Non-CME/CE Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus): AstraZeneca, Eli Lilly, Pfizer, Takeda

I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
 
Roy S. Herbst MD, PhD
Roy S. Herbst , MD, PhD
Ensign Professor of Medicine
Professor of Pharmacology
Chief of Medical Oncology
Director, Thoracic Oncology Research Program
Associate Director for Translational Research
Translational Research Program
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT
Disclosures
Consulting Fees: AstraZeneca, Eli Lilly, Genentech/Roche, Merck, Pfizer
Contracted Research: Genentech, Merck
Scientific Advisory Board: Biothera, Diatech, Kolltan
 

Faculty

Edward B. Garon MD
Edward B. Garon , MD
Associate Clinical Professor
Department of Medicine
Director, Thoracic Oncology Program
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, CA
Disclosures
Contracted Research: AstraZeneca, BMS, Genentech, Eli Lilly, Merck, Novartis, Iovance, Mirati, Dynavax

I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
 
Ronald B. Natale MD
Ronald B. Natale , MD
Director of the Lung Cancer Clinical Research Program
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA
Disclosures
Contracted Research: Merck, Tesaro, AstraZeneca, BMS
Other: Spouse is an AstraZeneca employee
 
Greg  Riely MD
Greg Riely , MD
Medical Oncologist
Thoracic Oncology Service
Vice Chair, Clinical Trials Office
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, NY
Disclosures
Contracted Research: Pfizer, Novartis, Roche, Takeda (funding to institution)

I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
 
Marianne  Davies DNP, ACNP, AOCNP
Marianne Davies , DNP, ACNP, AOCNP
Clinical Instructor in Nursing
Thoracic Oncology Program
Yale Comprehensive Cancer Center
Yale Schools of Nursing and Medicine
New Haven, CT
Oncology Pharmacist Faculty
Disclosures
Fees for Non-CME/CE Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus): Merck, BMS, Genentech, AstraZeneca
 
Richard  Gralla MD, FACP
Richard Gralla , MD, FACP
Professor of Medicine
Albert Einstein College of Medicine
Jacobi Medical Center
Bronx, New York
Disclosures
Consulting Fees (e.g., advisory boards): Merck, Helsinn
Fees for Non-CME/CE Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus): Merck, Helsinn, Purdue
Contracted Research: Merck

I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
 
Jim  Koeller MS
Jim Koeller , MS
Professor,
University of Texas at Austin
College of Pharmacy,
Pharmacotherapy Division
Adjoint Professor
University of Texas Health Science Center at San Antonio
School of Medicine, Pharmacotherapy Education & Research
University of Texas Health Science Center at San Antonio
San Antonio, TX
Disclosures
Fees for Non-CME/CE Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus): Lilly
 
Walter  Curran MD
Walter Curran , Jr. , MD
Executive Director, Winship Cancer Institute
Associate Vice President, Cancer,
Woodruff Health Sciences Center
Lawrence W. Davis Professor and Chairman of Radiation Oncology
Group Chairman and Principal Investigator, NRG
Atlanta, GA
Disclosures
Consulting Fees (e.g., advisory boards): BMS, AstraZeneca
 
Joel  Neal MD, PhD
Joel Neal , MD, PhD
Assistant Professor
Department of Medicine
Division of Oncology
Member, Stanford Cancer Institute
Stanford Clinical Cancer Center
Stanford, CA
Disclosures
Consulting Fees: Clovis, CARET/Physicians Resource Mgmt, Nektar, BI, ARMO Biosciences, ARIAD
Contracted Research: Genentech/Roche, Merck, Arqule, Novartis, Exelixis, BI, Nektar

I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
 
Deborah  Wong MD, PhD
Deborah Wong , MD, PhD
Professor, Oncology
Ronald Reagan UCLA Medical Center
UCLA Medical Center
Santa Monica, CA
Oncology Nursing Faculty
Disclosures
Consulting Fees: Bristol-Myers Squibb
 
11th Personalized Therapies and Best Clinical Practices for Lung Cancer and Head & Neck Cancer
11th Personalized Therapies and Best Clinical Practices for Lung Cancer and Head & Neck Cancer
Start Date: 01/30/2019
Date Expires: 01/30/2020

Agenda

SESSION #1: “INITIAL” Therapy for NONSQUAMOUS and SQUAMOUS NSCLC PATIENTS
What are the options for initial therapy of NONSQUAMOUS NSCLC?
  • Current algorithms, new and emerging therapies
  • Targeting PD-1, PD-L1, (Stratifying by PD-L1 Expression) Targeting CTLA-4
  • Targeting EGFR, ALK, ROS1, BRAF
  • Current and emerging various combinations of Immune & targeted therapies & chemotherapy
  • Chemotherapy monotherapy and in various combinations with Immune & targeted therapies

Edward B. Garon , MD
What are the therapeutic options for initial therapy of SQUAMOUS NSCLC? Which patients are candidates for the various options?
  • Current algorithms and new and emerging therapies
  • Targeting VEGFR2, PD-1, PD-L1, EGFR, ALK, ROS1, BRAF
  • Current and emerging various combinations of Immune & targeted therapies & chemotherapy
  • Chemotherapy monotherapy and in various combinations with Immune & targeted therapies

Paul A. Bunn , Jr. , MD
SESSION #2: Therapy Options “AFTER” 1st-Line Therapy for NONSQUAMOUS and SQUAMOUS NSCLC Patients
What are the standards of care options for second-line and subsequent lines of NSCLC therapy? What are these options? Which patients are candidates for these various options? And how are these therapies for relapsed NSCLC patients sequenced?
  • Chemotherapy
  • Targeting VEGFR2, PD-1, PD-L1, EGFR, ALK, ROS1, BRAF
  • Other Targets?

Ronald B. Natale , MD
DEBATE #1:Total Mutation Burden is a necessary clinical tool for managing NSCLC patients today.
  • YES (Dr. Herbst)
  • NO (Dr. Garon)

Edward B. Garon , MD
Paul A. Bunn , Jr. , MD
SESSION #3: The New Therapeutic Landscapes for ALK-REARRANGEMENT & EGFR-POSITIVE for NSCLC Patients
DEBATE #2: Should we use the most effective anti-ALK-directed therapy or anti-EGFR therapy "up front" or save it for relapse?
  • Use most effective agent "up front" (Dr. Bunn)
  • Save it for relapse (Dr. Herbst)

Paul A. Bunn , Jr. , MD
Roy S. Herbst , MD, PhD
ALK-NSCLC: 1st-Line Therapies and Sequencing Options: (1st, 2nd & 3rd-generation agents)
  • Should any of the FDA-approved anti-ALK targeted therapies be considered as The 1st-line standard of care?
  • What will be the impact of the emerging anti-ALK TKIs on the current treatment algorithm for treatment-naïve patients?
  • What are the strategies for intra-cranial disease control?

Paul A. Bunn , Jr. , MD
EGFR-NSCLC: 1st-Line Therapies and Sequencing Options: (1st, 2nd & 3rd-generation agents)
  • Should any of the EGFR-directed therapies be considered as The 1st-line standard of care?
  • What is the role for AR-mutation testing after patients relapse on up-front anti-EGFR therapy? And what is the test? and what is it looking for?
  • Should any patients with EGFR mutations receive immunotherapy? If Yes? Who? When?
  • What is the role for immune therapy in patients with EGFR mutations?

Greg Riely , MD
Emerging Options in Managing CNS disease in NSCLC: The expanding role of systemic therapies
H Jack West , MD
SESSION #4: Molecular Oncology BEYOND EGFR and ALK in NSCLC - Optimal Therapies - Diagnostic Testing
DEBATE #3: Should a medical oncologist delay therapy for a treatment-naïve NSCLC patient with either an EGFR, ROS-1 mutation or an ALK-re-arrangement while waiting for NGS testing results?
  • YES (wait for NGS test results before initiating therapy) (P. Bunn)
  • NO (treat without delay for the known driver mutation (EGFR, ROS-1, or ALK) (H. West)

Paul A. Bunn , Jr. , MD
H Jack West , MD
Treatment Options for Rarer NSCLC Mutations: Maximizing Targeted Therapy Opportunities
  • How does Broader FDA-approved NGS testing change what medical oncologists treating lung cancer are doing as standards of care?
  • What NSCLC molecular targets are most clearly relevant beyond EGFR, ALK and ROS1?

Joel Neal , MD, PhD
SESSION #5: Strategies for Early-Stage NSCLC - SCLC - Head & Neck Cancer
Early-Stage NSCLC
  • FDA-Approved anti-PD-L1 Mab for Stage III NSCLC
  • Are there potentially curable Stage III NSCLC patients treated with either Checkpoint Inhibition or Targeted Therapy?
  • Other anti-PD-L1 and PD-1 MAbs for Stage III NSCLC
  • What is the role of anti-PD-L1 and PD-1 MAbs for Stages I and II NSCLC?

Joel Neal , MD, PhD
Small Cell Lung Cancer (SCLC): New Advances with Systemic Therapy
  • Treatment-Naïve and Relapsed Patients
  • Targeted Therapies
  • Chemotherapy
  • Immune Therapies

Ronald B. Natale , MD
Radiation Therapy: New and Emerging Strategies for NSCLC
  • How should radiation be used with Checkpoint Inhibition for NSCLC patients?
  • What strategies should be used after chemo-radiation for Early-Stage NSCLC?
  • New strategies using radiation in the treatment of Stage IV NSCLC
  • New strategies using radiation for brain metastases

Walter Curran , Jr. , MD
Squamous Cell Cancer of the Head & Neck (SCCHN) New Advances with Checkpoint Inhibition-Based Strategies
  • For patients with progression on platinum-based therapy only?
  • Is there a role in up front therapy for Checkpoint Inhibition?

Deborah Wong , MD, PhD

Overview

This is an 8.25 hour CME/CE activity on the treatment and management of patients with lung cancer and head and neck cancer. The focus is on community-based medical oncology practices, but all clinicians caring for lung cancer patients are invited, including academic and research-based oncologists, pathologists and allied healthcare practitioners including nurses, nurse practitioners and pharmacists.

The primary objective is to provide the target audience with the practical knowledge and best clinical practices to help them improve outcome in their lung cancer and head and neck cancer patients through a focus on personalized medicine with molecular and genomic testing and biomarkers, especially today with the wider availability of NGS testing. This symposium will integrate many new and emerging therapies into best practices for their lung cancer and head and neck cancer patients including immune therapy, novel targeted therapies, and novel uses of chemotherapy in various combinations with immune therapies. The focus is on community-based practices, but all clinicians are targeted, including academic and research-based oncologists and allied healthcare professionals. The target audience includes lung cancer and head and neck cancer medical oncologists, pathologists, radiologists, surgeons, fellows, oncology pharmacists, oncology nurses, nurse practitioners, physician assistants and other allied healthcare professionals.


Educational Need

The educational need for this symposium on lung cancer and head and neck cancer is the result of recent and continuing FDA approvals and soon to emerge FDA approvals on new immune therapies, new targeted therapies as well as for a large number combinations of immune therapies with chemotherapies for thoracic malignancies. It is essential that this new data and corresponding clinical applications be integrated into the current standards of care. And the timing of this October 27, 2018 symposium, occurring immediately following the World Lung Cancer Meeting in Toronto and the ESMO Meeting in Europe greatly facilitates the education of clinicians treating lung cancer.

With an understanding of the most current clinical trials’ data and FDA indications involving immune and targeted therapies, it will be possible for HCPs to deliver optimal patient care for many malignancies, resulting in improved outcome.


Target Audience

This activity is designed to meet the educational needs of and help close the quality clinical performance practice gaps of medical oncologists, radiation oncologists, surgical oncologists, pathologists, physician assistants, oncology pharmacists, oncology nurses/Nurse Practitioners and other allied health-care professionals involved in the treatment, care and management of patients with lung cancer and Head & Neck Cancer, including physician assistants, fellows and other HCPs. Lung cancer and Head & Neck cancer are both treated optimally by a multi-disciplinary approach of clinicians and, thus, all of the aforementioned clinician specialties are targeted for invitation to this CME/CE activity for personalized therapies and best clinical practices.


Learning Objectives

Physician
  1. Understand how to select from among all options to provide the optimal therapy for treatment-naïve patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
  2. Evaluate when to order NGS testing for treatment-naïve patients with nonsquamous or squamous NSCLC, especially for those patients with EGFR mutations, or with ALK or ROS1 rearrangements.
  3. Compare and contrast the options for treating relapsed patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
  4. Evaluate how to apply the different various approved and emerging immune therapy monotherapy and combination strategies for NSCLC patients in both the treatment naïve and salvage settings.
  5. Compare and contrast the various immune therapy and chemotherapy options in treatment-naïve NSCLC without driver mutations in patients with high, low or no expression of PD-L1.
  6. Evaluate the scenarios for when, if ever, to temporarily discontinue, and when to resume immune therapy in a NSCLC patient that is responding to therapy.
  7. Evaluate the large number of open clinical trials offering various combinations of immune and targeted therapies for Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Head & Neck Cancer as possible options for enrolling eligible patients to possibly improve outcome.
  8. Compare and contrast the increasing number of options for treating NSCLC patients with an EGFR-directed therapy across all lines of therapy.
  9. Compare and contrast the increasing number of options for treating NSCLC patients with an ALK-directed therapy across all lines of therapy.
  10. Understand how to apply the various sequencing strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including when to use the most effective of the three generations of EGFR-directed and ALK-directed TKI therapies “up front” versus saving them for salvage therapy.
  11. Analyze the various predictive and prognostic markers including PD-L1, Tumor Mutation Burden (TMB) and smoking history for patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
  12. Evaluate the pros and cons of using Stereotactic Ablation Body Radiation (SABR) as an equivalent alternative standard of care to surgery for Stage I NSCLC patients.
  13. Understand the pros and cons of prophylactic cranial irradiation in NSCLC considering the advances with TKIs and other systemic therapy.
  14. Compare and contrast the new FDA-approved and emerging immune therapies and combinations for squamous cell Head & Neck cancer.
  15. Compare and contrast the emerging options for treating patients with Small Cell Lung Cancer.
  16. Evaluate the opportunities to address and improve priorities for the National Quality Strategy and Quality Improvement.
Nurse
  1. Recall how to select from among all options to provide the optimal therapy for treatment-naïve patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
  2. Describe when to order NGS testing for treatment-naïve patients with nonsquamous or squamous NSCLC, especially for those patients with EGFR mutations, or with ALK or ROS1 rearrangements.
  3. List the options for treating relapsed patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
  4. Review how to apply the different various approved and emerging immune therapy monotherapy and combination strategies for NSCLC patients in both the treatment naïve and salvage settings.
  5. Define the various immune therapy and chemotherapy options in treatment-naïve NSCLC without driver mutations in patients with high, low or no expression of PD-L1.
  6. Describe the scenarios for when, if ever, to temporarily discontinue, and when to resume immune therapy in a NSCLC patient that is responding to therapy.
  7. Identify the large number of open clinical trials offering various combinations of immune and targeted therapies for Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Head & Neck Cancer as possible options for enrolling eligible patients to possibly improve outcome.
  8. Recall the increasing number of options for treating NSCLC patients with an EGFR-directed therapy across all lines of therapy.
  9. Recall the increasing number of options for treating NSCLC patients with an ALK-directed therapy across all lines of therapy.
  10. Review how to apply the various sequencing strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including when to use the most effective of the three generations of EGFR-directed and ALK-directed TKI therapies “up front” versus saving them for salvage therapy.
  11. Describe the various predictive and prognostic markers including PD-L1, Tumor Mutation Burden (TMB) and smoking history for patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
  12. List the pros and cons of using Stereotactic Ablation Body Radiation (SABR) as an equivalent alternative standard of care to surgery for stage I NSCLC patients.
  13. List the pros and cons of prophylactic cranial irradiation in NSCLC considering the advances with TKIs and other systemic therapy.
  14. Recall the new FDA-approved and emerging immune therapies and combinations for squamous cell Head & Neck cancer.
  15. Review the emerging options for treating patients with Small Cell Lung Cancer
  16. Recall the opportunities to address and improve priorities for the National Quality Strategy and Quality Improvement.
Pharmacist
  1. Recall how to select from among all options to provide the optimal therapy for treatment-naïve patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
  2. Describe when to order NGS testing for treatment-naïve patients with nonsquamous or squamous NSCLC, especially for those patients with EGFR mutations, or with ALK or ROS1 rearrangements.
  3. List the options for treating relapsed patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
  4. Review how to apply the different various approved and emerging immune therapy monotherapy and combination strategies for NSCLC patients in both the treatment naïve and salvage settings.
  5. Define the various immune therapy and chemotherapy options in treatment-naïve NSCLC without driver mutations in patients with high, low or no expression of PD-L1.
  6. Describe the scenarios for when, if ever, to temporarily discontinue, and when to resume immune therapy in a NSCLC patient that is responding to therapy.
  7. Identify the large number of open clinical trials offering various combinations of immune and targeted therapies for Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Head & Neck Cancer as possible options for enrolling eligible patients to possibly improve outcome.
  8. Recall the increasing number of options for treating NSCLC patients with an EGFR-directed therapy across all lines of therapy.
  9. Recall the increasing number of options for treating NSCLC patients with an ALK-directed therapy across all lines of therapy.
  10. Review how to apply the various sequencing strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including when to use the most effective of the three generations of EGFR-directed and ALK-directed TKI therapies “up front” versus saving them for salvage therapy.
  11. Describe the various predictive and prognostic markers including PD-L1, Tumor Mutation Burden (TMB) and smoking history for patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
  12. List the pros and cons of using Stereotactic Ablation Body Radiation (SABR) as an equivalent alternative standard of care to surgery for stage I NSCLC patients.
  13. List the pros and cons of prophylactic cranial irradiation in NSCLC considering the advances with TKIs and other systemic therapy.
  14. Recall the new FDA-approved and emerging immune therapies and combinations for squamous cell Head & Neck cancer.
  15. Review the emerging options for treating patients with Small Cell Lung Cancer
  16. Recall the opportunities to address and improve priorities for the National Quality Strategy and Quality Improvement.

CME/CE Accreditation and Credit Designation

Physicians

The BioMedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The BioMedical Learning Institute designates this enduring activity for a maximum of 8.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses

The BioMedical Learning Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The BioMedical Learning Institute designates this educational activity for 8.25 contact hours.

Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Pharmacists

The BioMedical Learning Institute is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: coming
Credits: 8.25 hours (0.825 ceu)
Type of Activity: Knowledge

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Other

Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 8.25 hours of Category 1 credit for attending this symposium.

Fellows will receive a certificate of attendance that they can submit to their accrediting organizations for continuing education credit.

 

Educational Support

Sincere appreciation is extended to companies providing support for this independent educational activity.

Merck
Genentech
Celgene
AstraZeneca
Bristol-Myers Squibb
Foundation Medicine
Loxo Oncology

Cancer Grace

NCCN